Evolus Inc
NASDAQ:EOLS
Evolus Inc
Inventory
Evolus Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Evolus Inc
NASDAQ:EOLS
|
Inventory
$32.9m
|
CAGR 3-Years
15%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Inventory
$14.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Inventory
$2.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Pfizer Inc
NYSE:PFE
|
Inventory
$10.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Inventory
$6.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Inventory
$13.7B
|
CAGR 3-Years
47%
|
CAGR 5-Years
28%
|
CAGR 10-Years
15%
|
|
Evolus Inc
Glance View
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 167 full-time employees. The company went IPO on 2018-02-08. The Company’s first commercial product is Jeuveau, which is an approximately 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company offers customers and consumers a compelling value proposition with Jeuveau. BOTOX (onabotulinumtoxinA) is also an approximately 900 kDa botulinum toxin type A complex approved in the United States.
See Also
What is Evolus Inc's Inventory?
Inventory
32.9m
USD
Based on the financial report for Sep 30, 2025, Evolus Inc's Inventory amounts to 32.9m USD.
What is Evolus Inc's Inventory growth rate?
Inventory CAGR 5Y
46%
Over the last year, the Inventory growth was 121%. The average annual Inventory growth rates for Evolus Inc have been 15% over the past three years , 46% over the past five years .
